Syngene International has extended its strategic research collaboration with Bristol Myers Squibb (BMS) until 2035. The agreement broadens the scope of integrated services across drug development, reinforcing Syngene’s position as a strategic partner. This long-term collaboration, spanning over 25 years, aims to advance innovative therapies and improve patient outcomes worldwide.
Long-Term Partnership Secured
Syngene International announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb (BMS) through 2035. This expanded agreement covers a wide range of services within the drug development lifecycle.
Expanded Scope of Collaboration
The collaboration now includes integrated services across various stages, including:
- Discovery (chemistry, biology)
- Drug metabolism and pharmacokinetics
- Translational sciences
- Pharmaceutical development and manufacturing
- Clinical trials
- Data and information technology services
This expansion facilitates a seamless progression from research to commercialization.
Statements on the Extension
Peter Bains, Managing Director and CEO of Syngene International Ltd., stated, “Our collaboration with Bristol Myers Squibb, which now spans more than 25 years, is anchored in scientific excellence, operational reliability, and a shared commitment to advancing innovative therapies.”
Payal Sheth, Senior Vice President, Therapeutic Discovery Sciences, Bristol Myers Squibb, said, “At Bristol Myers Squibb, everything we do begins with patients. We greatly value our long-standing partnership with Syngene, which has been instrumental in advancing our scientific ambitions.”
BBRC’s Role
The collaboration began in 1998, leading to the establishment of the Biocon Bristol Myers Squibb Research and Development Center (BBRC), fully commissioned in 2009. The BBRC supports integrated capabilities across target identification, lead discovery, and various other areas. Currently, around 700 Syngene scientists work at the center, contributing to discovery and preclinical development across multiple therapeutic areas.
Source: BSE
